423 related articles for article (PubMed ID: 19628297)
1. Plasmacytoid dendritic cells in autoimmune diabetes - potential tools for immunotherapy.
Nikolic T; Welzen-Coppens JM; Leenen PJ; Drexhage HA; Versnel MA
Immunobiology; 2009; 214(9-10):791-9. PubMed ID: 19628297
[TBL] [Abstract][Full Text] [Related]
2. Dendritic cell subsets and type I diabetes: focus upon DC-based therapy.
Lo J; Clare-Salzler MJ
Autoimmun Rev; 2006 Jul; 5(6):419-23. PubMed ID: 16890897
[TBL] [Abstract][Full Text] [Related]
3. The role of interferon alpha in initiation of type I diabetes in the NOD mouse.
Li Q; McDevitt HO
Clin Immunol; 2011 Jul; 140(1):3-7. PubMed ID: 21592863
[TBL] [Abstract][Full Text] [Related]
4. CD8+ T cells in type 1 diabetes.
Tsai S; Shameli A; Santamaria P
Adv Immunol; 2008; 100():79-124. PubMed ID: 19111164
[TBL] [Abstract][Full Text] [Related]
5. Provision of antifungal immunity and concomitant alloantigen tolerization by conditioned dendritic cells in experimental hematopoietic transplantation.
Montagnoli C; Perruccio K; Bozza S; Bonifazi P; Zelante T; De Luca A; Moretti S; D'Angelo C; Bistoni F; Martelli M; Aversa F; Velardi A; Romani L
Blood Cells Mol Dis; 2008; 40(1):55-62. PubMed ID: 17827038
[TBL] [Abstract][Full Text] [Related]
6. Dendritic cells expressing BTLA induces CD8+ T cell tolerance and attenuates the severity of diabetes.
Li S; Zhang M; Xiang F; Zhao J; Jiang C; Zhu J
Vaccine; 2011 Oct; 29(44):7747-51. PubMed ID: 21827810
[TBL] [Abstract][Full Text] [Related]
7. Heightened interferon-alpha/beta response causes myeloid cell dysfunction and promotes T1D pathogenesis in NOD mice.
Peng RH; Paek E; Xia CQ; Tennyson N; Clare-Salzler MJ
Ann N Y Acad Sci; 2006 Oct; 1079():99-102. PubMed ID: 17130537
[TBL] [Abstract][Full Text] [Related]
8. Is lack of peripheral tolerance induction a cause for diabetes in the non-obese diabetic mouse?
Lund T; Strid J
Arch Immunol Ther Exp (Warsz); 2000; 48(5):405-16. PubMed ID: 11140468
[TBL] [Abstract][Full Text] [Related]
9. Peptide-pulsed immature dendritic cells reduce response to beta cell target antigens and protect NOD recipients from type I diabetes.
Lo J; Peng RH; Barker T; Xia CQ; Clare-Salzler MJ
Ann N Y Acad Sci; 2006 Oct; 1079():153-6. PubMed ID: 17130547
[TBL] [Abstract][Full Text] [Related]
10. Both central and peripheral tolerance mechanisms play roles in diabetes prevention in NOD-E transgenic mice.
Mellanby RJ; Phillips JM; Parish NM; Cooke A
Autoimmunity; 2008 Aug; 41(5):383-94. PubMed ID: 18568644
[TBL] [Abstract][Full Text] [Related]
11. Disease-modifying immunotherapy for the management of autoimmune diabetes.
Castro CN; Barcala Tabarrozi AE; Noguerol MA; Liberman AC; Dewey RA; Arzt E; Morelli AE; Perone MJ
Neuroimmunomodulation; 2010; 17(3):173-6. PubMed ID: 20134195
[TBL] [Abstract][Full Text] [Related]
12. Do immunotherapy and beta cell replacement play a synergistic role in the treatment of type 1 diabetes?
Li DS; Warnock GL; Tu HJ; Ao Z; He Z; Lu H; Dai LJ
Life Sci; 2009 Oct; 85(15-16):549-56. PubMed ID: 19747492
[TBL] [Abstract][Full Text] [Related]
13. Innate immunity in type 1 diabetes.
Diana J; Gahzarian L; Simoni Y; Lehuen A
Discov Med; 2011 Jun; 11(61):513-20. PubMed ID: 21712017
[TBL] [Abstract][Full Text] [Related]
14. Transient upregulation of indoleamine 2,3-dioxygenase in dendritic cells by human chorionic gonadotropin downregulates autoimmune diabetes.
Ueno A; Cho S; Cheng L; Wang J; Hou S; Nakano H; Santamaria P; Yang Y
Diabetes; 2007 Jun; 56(6):1686-93. PubMed ID: 17360980
[TBL] [Abstract][Full Text] [Related]
15. Dendritic cell mediated therapy for immunoregulation of type 1 diabetes mellitus.
Phillips BE; Giannoukakis N; Trucco M
Pediatr Endocrinol Rev; 2008 Jun; 5(4):873-9. PubMed ID: 18552749
[TBL] [Abstract][Full Text] [Related]
16. Dysrulation of T cell peripheral tolerance in type 1 diabetes.
Tisch R; Wang B
Adv Immunol; 2008; 100():125-49. PubMed ID: 19111165
[TBL] [Abstract][Full Text] [Related]
17. The potential role of dendritic cells in the therapy of Type 1 diabetes.
Lee CN; Lew AM; Wu L
Immunotherapy; 2013 Jun; 5(6):591-606. PubMed ID: 23725283
[TBL] [Abstract][Full Text] [Related]
18. Curative and beta cell regenerative effects of alpha1-antitrypsin treatment in autoimmune diabetic NOD mice.
Koulmanda M; Bhasin M; Hoffman L; Fan Z; Qipo A; Shi H; Bonner-Weir S; Putheti P; Degauque N; Libermann TA; Auchincloss H; Flier JS; Strom TB
Proc Natl Acad Sci U S A; 2008 Oct; 105(42):16242-7. PubMed ID: 18852471
[TBL] [Abstract][Full Text] [Related]
19. New type of human blood stem cell: a double-edged sword for the treatment of type 1 diabetes.
Zhao Y; Lin B; Dingeldein M; Guo C; Hwang D; Holterman MJ
Transl Res; 2010 May; 155(5):211-6. PubMed ID: 20403575
[TBL] [Abstract][Full Text] [Related]
20. The countervailing actions of myeloid and plasmacytoid dendritic cells control autoimmune diabetes in the nonobese diabetic mouse.
Saxena V; Ondr JK; Magnusen AF; Munn DH; Katz JD
J Immunol; 2007 Oct; 179(8):5041-53. PubMed ID: 17911589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
